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Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the accumulation of α-Synuclein (a-Syn)
into Lewy body inclusions and the loss of dopaminergic neurons in the substantia nigra (SN). Accumulation of
a-Syn can induce a progressive, cyclical pathology that results in the transmission of toxic, aggregated a-Syn species
to healthy neurons, leading to further neurodegeneration such as occurs in PD. The blood–brain barrier (BBB) and
blood-cerebrospinal fluid (CSF) barriers (BCSFB) are responsible for regulating the access of nutrients and other
molecules to the brain, but very little is known about their regulatory roles in maintaining the homeostasis of a-Syn
in the CSF and brain parenchyma. This review analyzes the current literature reports on the transport of a-Syn by
various brain cell types with a particular focus on the potential transport mechanisms of a-Syn at the BBB and
BCSFB. The indication of altered a-Syn transport by brain barriers in PD pathoetiology and the perspectives in this
research area are also discussed.
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Introduction
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disease after Alzheimer’s disease and typic-
ally affects those above the age of 60 [1]. PD is primarily
defined by symptoms of motor impairment, i.e., resting
tremor, rigidity, hypokinesia, and postural instability.
Psychiatric problems (i.e. depression) and cognitive defi-
cits are additional symptoms that have been associated
with PD [2]. PD occurs in two general forms: sporadic and
familial (genetic). The former occurs due to environ-
mental exposure to a variety of toxicants that interact
with vulnerable genes, and the latter involves genetic fac-
tors, e.g. point mutations and truncations that can occur
in a variety of proteins [2]. Surviving neurons possess
intra-cytoplasmic inclusions called Lewy bodies (LB) and/
or Lewy neurites (LN) [3]. While these inclusions are
present in the substantia nigra in the later stages of PD de-
velopment (i.e. when PD can be clinically diagnosed), the
inclusions have been shown to appear in other structures* Correspondence: wzheng@purdue.edu
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article, unless otherwise stated.of the brainstem, e.g. anterior olfactory structures and the
medulla oblongata [3] prior to their appearance at the
substantia nigra. Furthermore, LBs/LNs are also present
in the cerebral cortex in the final stages of PD [3]. These
findings show that while the substantia nigra may be
the prominent site of neurodegeneration, the dysfunction
of α-synuclein (a-Syn) and the production of LBs/LNs
begin elsewhere in the brain. This clearly indicates that
the pathology contributing to the production of LBs/LNs
propagates to other regions of the brain. An integral char-
acteristic of LBs and LNs is that they are mainly comprised
of the protein a-Syn [4]. The pathology of this protein is
a hallmark of many neurological disorders including PD
(e.g., multiple system atrophy, dementia with Lewy bodies,
etc.) that have been grouped into a class of disorders
called a-synucleinopathies.
The a-Syn protein is a small (~14.5 kDa), naturally un-
folded protein expressed in a variety of cell types including
neurons. The wild-type function of a-Syn is unknown, but a
variety of functions have been proposed in recent literature.
Potential functions of a-Syn at the neuronal synapse include
vesicular stabilization [2], synaptic pool maintenance [5],
regulation of dopamine synthesis [6], and a potential rolentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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Bates and Zheng Fluids and Barriers of the CNS 2014, 11:17 Page 2 of 9
http://www.fluidsbarrierscns.com/content/11/1/17in synaptic plasticity [7]. Additionally, an a-Syn-knockout
murine model shows compromised complex I/III activity
at the electron transport chain and changes in lipid com-
position of mitochondrial membranes [8]. The aggregation
of a-Syn not only compromises synaptic functionality, but
also the energy production at the mitochondria, which is
clearly essential for all cell types [9]. These findings show
that a-Syn is potentially involved in a variety of critical
cellular processes in neurons. Unfortunately, the function
of a-Syn in other cell types has yet to be elucidated.
Aggregation of a-Syn and ensuing development of a-Syn
fibrils precede the development of Lewy bodies that con-
tain highly aggregated a-Syn molecules. The most toxic
species of a-Syn are the soluble, oligomeric species that
are initially formed by the aggregation of a-Syn monomers
[10]. The oligomeric species can then develop into larger,
mature, insoluble fibrils of a-Syn that eventually assimilate
into the insoluble, cytoplasmic LBs and LNs present in
surviving neurons [10]. The process of a-Syn aggregation
can be induced in a variety of pathways that range from
mutations in various proteins including a-Syn to synaptic
oxidative stress. More specifically, various mutations of
a-Syn including point mutations (e.g. A53T, A30P, E46K),
truncation, duplication, or triplication can result in the loss
of wild-type function and an increased propensity to aggre-
gate into fibrils [2,10,11]. Additionally, the overexpression
of a-Syn in animal models has shown an increased a-Syn
expression and the manifestation of PD-like symptoms
with respect to controls [12-14].
Little is known about how a-Syn is regulated in the
brain. Previous research has shown that wild-type and
toxic species of a-Syn can be released by neurons to the
interstitial fluid (ISF), which merges with the cerebro-
spinal fluid (CSF) [15-17]. While most molecules are
cleared from the CSF by the choroid plexus or by drain-
age from the subarachnoid spaces to the blood [18,19],
the clearance of aggregated a-Syn via the CSF remains
unknown. It is possible that the blood-CSF barrier
(BCSFB) in the choroid plexus may play a role in main-
taining healthy a-Syn levels in the central milieu. In this
review, the concepts and main functions of brain barrier
systems, i.e., the blood–brain barrier (BBB) and BCSFB
will be introduced. The current understanding on how
a-Syn is transported by the neurons is then discussed,
which is followed by a review of the current understan-
ding of a-Syn transport by brain barriers and possible
mechanisms underlying a-Syn transport. Finally, the
indication of altered a-Syn transport by brain barriers in
PD pathoetiology and the perspectives in this research
area are discussed.
The blood–brain barrier and blood-CSF barrier
Brain extracellular fluids consist of the CSF in the brain
ventricles and interstitial fluids (ISF) between the neuronsand glia (Figure 1). The blood–brain barrier (BBB) sepa-
rates the blood from the ISF and regulates the chemical
stability of microenvironment of the brain. The BBB ope-
rates as a dynamic boundary between the cerebral vascula-
ture and brain parenchyma, which is highly susceptible to
hypoxia, inflammation, endogenous and exogenous insults
and other stressors [20]. The BBB consists of (1) endothe-
lial cells comprising the brain capillaries, (2) the basement
membrane, (3) the pericytes that surround the endothelia
and regulate endothelium inflammation and homeostasis,
and (4) the astrocytic glial cells that support the proper
functioning of endothelia and provide a direct link be-
tween cerebral vasculature and neurons via their unique
cap-like structures called end-feet [20-23]. The individual
endothelial cells are linked by tight junctions, which are
more complex than those of most other vascular endothe-
lia [22,24]. As a result, the paravascular diffusion of hydro-
philic molecules that occurs in other endothelia does not
occur at the BBB [22,24,25]. The most important role of
the BBB is protecting the brain against abrupt fluctuations
in blood chemistry (e.g. nutrients, hormones, toxicants,
etc.) [24]. Also, the BBB is responsible for the distribution
and regulation of the various neurotransmitters used by
both the central and peripheral nervous systems [24].
While ionic and hydrophilic molecules are primarily
admitted by the BBB via specialized transporters, the per-
meability of macromolecules and other solutes depends
on their size and lipophilicity [22].
The blood-CSF barrier (BCSFB) separates the blood
circulation from the CSF (Figure 1) and functions within
the highly vascularized choroid plexus located in each of
the four brain ventricles [18,19]. The BCSFB is comprised
of (1) an apical layer of polarized epithelial cells that face
the CSF, (2) supportive connective tissue underlying the
epithelial cells, and (3) a basal layer of endothelial cells
that faces the blood [18]. The microvilli present on the
apical surface of choroidal epithelia increase total sur-
face area of the BCSFB, providing an enhanced ca-
pability of uptake by the BCSFB [26]. Furthermore, the
relatively large volume of CSF is constantly filtered and
secreted by the choroid plexus cells located strategically in
the aforementioned ventricles within the brain [19]. The
blood flow to the choroid plexus is approximately 5–10
times greater than its flow to other brain regions, which
further fortifies the hypothesis of a general cleansing role
of the BCSFB [18,26]. Substantial evidence has accrued
showing the BCSFB’s ability to clear undesirable contents
from the CSF [24-27].
Like the BBB, the tight junctions at the apical layer of
the epithelial cells are the structural basis of the BCSFB,
which are essential to maintaining barrier function of
the BCSFB, due to the naturally leaky and fenestrated
endothelium [26]. The CSF is produced by the plexus
epithelial cells from water and solutes filtered from the
Figure 1 Proposed disposition of α-Synuclein in neurons, glia, and brain barrier systems. Both free and aggregated species of a-Syn are
transported between neurons or from neurons to various glial cell types. Uptakes of a-Syn species by astrocytes at the BBB and choroidal
epithelia at the BCSFB are known to be mediated by the receptor-mediated endocytosis and clathrin-mediated endocytosis, respectively.
The influx transport of a-Syn from the blood to the ISF via the BBB or from the blood to the CSF via the BCSFB is currently unknown,
neither is the clearance of a-Syn to the blood by either barrier system.
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variety of molecules that can potentially accumulate
from the ISF [19]. The contents of the CSF are regulated
by the BCSFB as the CSF cycles from the brain, through
the BCSFB in the ventricles, throughout the spinal cord,
and finally through the subarachnoid space to the blood
[19,26]. The CSF, in concert with the BCSFB in the cho-
roid plexus, could potentially carry a-Syn species that are
released by neurons to the choroid plexus for clearance.
α -Synuclein transport by neurons
The increased aggregation of a-Syn found in PD could
be the result of 1) the increased production of a-Syn by
neural processes, (2) the inter-neuronal transmission oftoxic a-Syn aggregated species, 3) the decreased ability
for brain to prevent a-Syn from aggregation and against
its toxicity, or 4) a combination of the these concepts. a-
Syn was originally viewed as an intracellular protein and
not capable of being transported out of the cell. Recent
studies have provided evidence that contradict this theory.
Studies have shown that a-Syn molecules are packaged
into vesicles, suggesting that a-Syn can be exported from
the cell via exocytosis [15]. Indeed, both monomer and
aggregated species of a-Syn are released via exocytosis
following intravesicular localization [15]. Furthermore,
this process is accelerated in conditions of mitochondrial
dysfunction and reduced proteosomal degradation [15],
which are both symptoms of PD pathology at the cellular
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shows that reduced autophagy in neurons also induces the
release of a-Syn aggregates via exocytosis; the increased
a-Syn exocytosis has been correlated with the increased
apoptotic activity in nearby neurons [16]. These findings
clearly illustrate the neurons’ capability to eject toxic a-Syn
aggregates into the ISF. However, the release of a-Syn aggre-
gates is merely the one half of the cell-to-cell transmission
mechanism, which invites the question: what mechanism(s)
is/are responsible for the uptake of these extracellular
a-Syn aggregates in healthy, neighboring neurons?
The experiment of grafting of healthy neurons with un-
healthy neurons possessing a-Syn aggregates can result in
a-Syn aggregation in previously healthy neurons [28,29]. A
more in-depth study shows that the mechanism under-
lying the uptake of these aggregates is endocytosis [28].
This finding confirms that a-Syn aggregates can be trans-
ported inter-cellularly via exocytosis and endocytosis. Other
researchers have provided additional evidence that sup-
ports endocytosis as a mechanism for a-Syn aggregate
uptake [30]. It is also believed that a-Syn is taken up by
neurons via different mechanisms depending on the
species of a-Syn. Monomer a-Syn can diffuse across the
membrane in a passive manner, while the aggregated spe-
cies are taken up by endocytosis, which is thought to be
receptor-mediated [30]. Interestingly, the findings from
this group have also suggested that neurons take up a-Syn
aggregates in an attempt to degrade the inclusions while
sparing a-Syn monomers from degradation [30]. Due to
the aforementioned compromised autophagy in neurons
afflicted with a-Syn aggregates, these inclusions are free to
induce further intracellular damage including the exten-
sion of a-Syn polymerization. Additionally, a more recent
study indicates that extracellular a-Syn aggregates can in-
duce lysosomal rupture following uptake via cell-to-cell
transmission [31]. Therefore, the aggregates may attack
the mechanisms required for their clearance in neurons
while simultaneously exacerbating intracellular toxicity.
At the cellular level, PD pathology is initiated when a-
Syn aggregates are unable to be degraded by the afflicted
neurons, which facilitates their export from the cell via
exocytosis. These extracellular polymers then promote this
vicious cycle in neighboring cells after being taken up from
the ISF via endocytosis. These inclusions wreak additional
havoc within the cell by inducing lysosomal rupture, mito-
chondrial dysfunction, continued a-Syn aggregation, and
eventual apoptosis while simultaneously extending this
cycle of pathology [9,17,31,32]. This pathology can be com-
bated with therapeutic strategies including reversing the
aggregation of a-Syn and enhancing the cells’ ability to de-
grade these polymers. One potential therapeutic strategy
would be to strengthen the ability of the barriers to clear
these aggregates from the brain, so that they can be
degraded elsewhere in the body. This strategy cannot beemployed without a fundamental understanding of a-Syn
transport and regulation by these barriers.
α-Synuclein transport by astrocytes: implications in BBB
transport
Astrocytes are an integral part of the BBB (Figure 1). The
nature of the BBB in regulating which molecules are ac-
cessible to the brain, places the system in an ideal position
to assist in the uptake and clearance of a-Syn between the
ISF and blood. The BBB may possess a therapeutic advan-
tage over the BCSFB because of its immediate contact with
neurons that border cerebral vasculature via the astrocytes
[33]. Consequently, any clearance of neuronal-derived a-
Syn by the BBB would likely begin with the astrocytes,
and thus the ability of astrocytes to transport a-Syn aggre-
gates to the endothelial cells is critical to the release of
a-Syn to the blood (Figure 1). Previous research, however,
shows that the BBB potentially does more harm than good
in attempts to clear toxic a-Syn species from neurons and
the ISF. Initial evidence has shown the presence of aggre-
gated a-Syn species in astrocytes of post-mortem PD pa-
tients [34,35]. However, the research does not provide any
evidence pertaining to the mechanisms behind the appear-
ance of these accumulations in astrocytes. Interestingly, a
hypothesis has since been developed that these a-Syn in-
clusions originate from outside the cell and are being
absorbed by the astrocytes [35]. Another research group
later confirmed this hypothesis; their research shows that
astrocytes acquire extracellular a-Syn aggregates via endo-
cytosis [36,37]. In a set of experiments, Lee and colleagues
have shown that rat primary astrocytes take up a-Syn ag-
gregates (1) from conditioned medium containing a-Syn
aggregates collected from differentiated SH-SY5Y cells
and (2) when co-cultured with SH-SY5Y cells that over-
express a-Syn. Astrocytes transfected with a dynamin-1
K44A mutation, which prevents endocytosis via the inhi-
bition of endocytic vesicle formation, show a significant
decrease in a-Syn uptake [37]. These results confirm the
primary mechanism of a-Syn uptake is by endocytosis. In
addition, this group of investigators has also shown that
glial a-Syn accumulation occurs in a-Syn overexpressing
transgenic (tg) mice compared to APP tg and non-tg
control mice, where a-Syn is present only in neurons [37].
Finally, this group has shown that a-Syn glial accumulation
induces pro-inflammatory gene expression and cytokine
production, suggesting that the uptake of extracellular
a-Syn can lead to cellular toxicity in astrocytes [37].
It must be emphasized that the astroglial a-Syn toxicity
appears to be very similar to the a-Syn pathology pathway
seen in neurons including the death of afflicted astrocytes.
Another factor to consider with respect to a-Syn clearance
by the BBB is the endogenous expression of a-Syn by this
barrier. The endogenous expression of a-Syn in astrocytes
has recently been illustrated in primary cultures of rat
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lular toxic a-Syn species that enter astrocytes could gener-
ate new a-Syn oligomers and fibrils in astrocytes, which
would also contribute to cell stress and death. The similar-
ity between a-Syn dysfunction in neurons and astrocytes
alludes to the inability of the BBB to degrade or clear toxic
a-Syn species from brain. Interestingly, the similarities be-
tween the a-Syn pathologies of neurons and astrocytes
also suggest, albeit remotely, that reversing a-Syn aggrega-
tion may be an effective therapeutic strategy in neurons,
astrocytes, and other glial cell types. If the BBB is to be
utilized therapeutically to clear toxic a-Syn species from
the brain, astrocytes should become a prime therapeutic
target for their role of the first contact with a-Syn in brain
parenchyma. Furthermore, the expression and behavior
of a-Syn in other cell types of the BBB must be investi-
gated. For example, endothelial cells from human cerebral
blood vessels have been shown to express a-Syn mRNA in
previously-published literature [38]. More investigation in
the expression and transport of a-Syn species by all cell
types of the BBB is needed in order to fully understand
the potential for a-Syn pathology throughout the BBB
and establish any potential therapeutic strategies invol-
ving this barrier.
α-Synuclein transport by choroidal epithelia: implications
in BCSFB clearance
While there is still much unknown about a-Syn trans-
port by the BBB, even less is known about the role of
the BCSFB in regulating a-Syn in the CSF. The BCSFB is
capable of clearing materials from the brain; but little in-
formation in the current literature suggest a potential
pathway for the BCSFB to clear toxic a-Syn species
present in the CSF. Additionally, the extent to which the
BCSFB produces endogenous a-Syn was unknown. A
clear difference between the BBB and BCSFB is that the
BCSFB does not have a direct cellular link to neurons.
Rather, the BCSFB plays a role in brain homeostasis via
the regulation of the CSF that surrounds and immerses
brain parenchyma. This raises the question of whether
this position of the BCSFB provides an advantage in the
clearance of toxic a-Syn species or whether it places the
BCSFB at an even greater risk of a-Syn-induced damage
compared to the BBB.
It has been suggested that most of the a-Syn found in
the brain and CSF is produced by neurons and/or neur-
oglia [39]. Yet, a smaller, secondary source of a-Syn may
originate from transport from the blood to CSF (Figure 1).
Naturally, this raises the question as to how the BCSFB in
the choroid plexus regulates a-Syn in the CSF, if at all.
Recent longitudinal studies have shown the blood concen-
tration of a-Syn can be as high as about 3.5 μg/mL [40].
This is over 1000-fold higher in comparison to the CSF
[40-42]. There is also evidence showing that a-Syn mRNAis expressed by erythrocytes [43,44]. However, it remains
unknown whether the fraction of a-Syn content in blood
originates from organs other than the brain or is derived
from the CNS. The exponentially higher a-Syn level found
in the blood compared to CSF suggests that the BCSFB
must actively maintain a-Syn levels in the CSF against a
sharp concentration gradient between the blood and the
CSF. Therefore, if the BCSFB could clear a-Syn from the
CSF, it must perform this function via some type of
energy-dependent active transport in order to transport a-
Syn against this concentration gradient. While the pres-
ence of a-Syn in the CSF has been confirmed by previous
research [39,41,42], the actual transport of a-Syn across
the BCSFB and the mechanism(s) involved are currently
unknown. The evidence of intracellular and cell-to-cell a-
Syn transport via endocytosis in neurons and astrocytes
[28,30,45] suggests that a-Syn could be transported by
endocytosis at the BCSFB.
Recent data from this laboratory have identified the pres-
ence of the mRNA encoding a-Syn as well as a-Syn pro-
teins in choroid plexus tissue collected from rats; similar
expression of a-Syn was also found in rat choroidal pri-
mary cells as well as in an immortalized rat choroid epithe-
lial Z310 cell line (Figure 2) [45,46]. We suspect that this
expression of a-Syn may play a role in a-Syn pathology
and contribute to the development of a-Syn aggregates.
Similar to the pathological pathway in astrocytes, the
BCSFB may attempt to clear a-Syn aggregates from the
CSF via the uptake of these polymers, which provides an
opportunity for these polymers to interact with endoge-
nous a-Syn in cells of the BCSFB and promote cell stress
and accelerated a-Syn pathology.
Recent studies from this laboratory also show that the
BCSFB is capable of taking up a-Syn molecules from the
CSF. When immortalized Z310 rat choroidal epithelial
cells were stained for a-Syn, the expression of naturally
existing a-Syn in control Z310 cells was evident (Figure 2)
[46]. Furthermore, by incubating the cells with 0.5 μM
a-Syn for 5 hours, an increased fluorescent signal in the
cells became evident; this suggests that the BCSFB cells
have the ability to take up a-Syn from the extracellular
medium [46]. The cells were also simultaneously stained
for clathrin, a protein that forms the coated vesicles and
nonspecifically transports large molecules into the cells by
endocytosis [48]. The immunocytochemical data clearly
showed that the fluorescent signals of a-Syn were co-
localized with signals from clathrin (Figure 2). More inter-
estingly, the clathrin-fluorescent signal increased following
a-Syn treatment with respect to controls, indicating
an up-regulated expression of clathrin in response to
the presence of external a-Syn. These data suggest that
clathrin-mediated endocytosis appears to be, at least
partially, responsible for a-Syn uptake in choroidal Z310
cells [46].
Figure 2 Expression of α-Synuclein and clathrin in Z310 cells with or without a-Syn treatment in a typical experiment (n = 5). Z310
cells are immortalized rat choroidal epithelial cells established in this laboratory [47]. The cells were treated with or without 0.5 μM recombinant
human a-Syn for 5 hours prior to immunostaining with the primary antibodies, followed by fluorescent secondary antibodies. Fluorescent
signals for a-Syn and clathrin are shown in green and red, respectively. Merged images show a co-localization of a-Syn signals with those
of clathrin.
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mer a-Syn across the BCSFB via an in vitro model that
utilizes rat primary choroid plexus cells cultured on a
permeable membrane of a Transwell chamber [49]. Our
results showed that after 24 and 48 hours of incubation
with a-Syn from the apical side of the barrier, the BCSFB
monolayer was capable of establishing and maintain-
ing an a-Syn gradient, with a significant majority of
the a-Syn on the basal side of the barrier, i.e. the blood
side [49]. These data clearly show that the BCSFB is
capable of transporting a-Syn between the blood and
the CSF. Our observations may provide a foundation
for understanding the role of the BCSFB in a-Syn trans-
port between the CSF and the blood. This enables fu-
ture avenues of research to be explored including (1)
the BCSFB’s ability to clear toxic a-Syn species from the
CSF, (2) the mechanism(s) behind the uptake of a-Syn
by the BCSFB, and (3) the role, if any, endogenous ex-
pression of a-Syn might play in potential a-Syn-related
pathological pathways at the BCSFB. Understanding
the relationship between a-Syn and the BCSFB is
essential in order to ascertain the BCSFB’s potential role
in PD pathology. Also, understanding this phenomenon
could assist with understanding other neurodegenerative
disorders, clarify the potential of a-Syn in the CSF as a re-
liable biomarker for PD, and assess the BCSFB’s potential
as a therapeutic target for PD.Toxicological implication of a-Syn transport at brain
barriers
There is an abundance of factors involving the progres-
sion of neurodegeneration that have yet to be reported
in relation to a-Syn transport by the blood–brain barriers.
Most cases of sporadic PD are considered to be idiopathic,
but it is generally believed that the disease is a result of
unknown environmental factors [49]. Recent evidence has
suggested that some of these cases may be related to
the exposure to environmental factors including heavy
metals and pesticides [50,51]. Exposure to such factors
could have significant effects on a-Syn regulation by both
barriers and possibly contribute to PD pathology. For
example, our lab has shown that toxic manganese expos-
ure can induce aggregation and altered uptake of a-Syn
in rat primary choroid plexus cells within 2 hours [49].
In addition, there are many genetic mutations in proteins
other than a-Syn that contribute to a-Syn toxicity and PD
development [52,53]. The G2019S LRRK2 mutation, the
most common mutation found in familial PD phenotypes,
has been showed to interact with a-Syn during chaperone-
mediated autophagy and consequently, promote a-Syn
dysfunction [54]. These and various other factors could
likely play critical roles in a-Syn regulation by the BBB
and BCSFB from the standpoint that these factors are det-
rimental to brain health and must be countered effectively.
As research in these areas progresses, a new answer may
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tween the blood–brain barriers and a-Syn therapeutically.
Conclusions
The current understanding of a-Syn transport by various
cell types in the BBB and BCSFB as well as in neurons is
summarized in Table 1. In general, the amount of inves-
tigation into the relationship between the blood–brain
barriers and a-Syn pathology in PD remains miniscule.
Consequently, very little is known about these relation-
ships. With the limited information, we propose a tenta-
tive scheme of a-Syn disposition in brain and further
suggest that pertinent research is needed to advance the
field (Figure 1). For a-Syn transport from blood to ISF via
the BBB, it is currently unknown whether brain endothelial
cells possess the receptor-mediated or clathrin-mediated
endocytosis, which could take up a-Syn molecules from
the systemic circulation and serve as the source of a-Syn
in brain parenchyma. We also do not know how a-Syn is
transferred from cerebral endothelia to astrocytes prior to
reaching neurons, or vice versa, from astrocytes to endo-
thelia. These interesting questions could serve well as the
research objectives for understanding a-Syn transport by
the BBB.
Within brain parenchyma, the ultimate fate of a-Syn,
specifically toxic, aggregated species, following the release
from neurons (and other cell types), remains elusive. Neu-
rons are known to produce a-Syn, and by exocytosis releaseTable 1 Studies and findings on the uptake and release of a-S
Cell type a-Syn transport
Blood–brain
barrier (BBB)
1) Astrocytes: Endogenously expresses a-Syn. Astrocytes ta
activation occurs upon uptake of a-Syn aggregates. Ast
2) Endothelia: endothelia of cerebral blood vessels expres
expression of a-Syn was found in BBB endothelia.
3) Perictyes: Unknown
4) Basal Lamina: Unknown
Blood-CSF
barrier (BCSFB)
Choroid Epithelia: Immortalized Z310 cells express a-Syn e
clathrin is upregulated during a-Syn exposure. Primary CP
endogenously and take up free a-Syn.
Neurons Neurons are capable of both the uptake and secretion of
secreted and taken up by neurons. Cell-to-cell transmissio
multiple glial types (e.g. astrocytes, microglia, etc.)
Glia (excl.
astrocytes)
1) Microglia: Microglia take up free and toxic a-Syn aggreg
activation upon uptake of a-Syn.
2) Oligodendrocytes: Uptake of aggregated a-Syn was sho
Consequently, intracellular inclusions containing a-Synfree and/or aggregated a-Syn species to the ISF, which re-
sults in the exposure of toxic a-Syn species to neighboring
neurons and glia. Most of the neural cell types are capable
of degrading free or small, oligomeric a-Syn species; thus,
the influx of these a-Syn aggregate species could poten-
tially start the intracellular, pathological cycle of a-Syn
aggregation, cell damage and death, and the eventual
release of additional toxic forms of a-Syn to nearby cells
[36,37,55,56]. Astrocytes, for example, can absorb these
polymers via receptor-mediated endocytosis. This could
lead to cellular injury and apoptosis, which may also com-
promise the BBB to some degree. Accumulation of a-Syn
in astrocytes would logically lead to the assumption that
a-Syn may be transported out of brain by the BBB. How-
ever, there is no report in literature showing evidence to
substantiate this hypothesis.
Recent data have provided the evidence of endogenous
a-Syn expression in the choroidal epithelial cells in the
BCSFB and the ability of the BCSFB to transport a-Syn
across a primary BCSFB monolayer in vitro. This finding
can be used as a launching point for future investiga-
tions to further explore the relationship between a-Syn,
the BCSFB, the external factors that can induce a-Syn dys-
function at the BCSFB, and how that dysfunction can alter
the physiology and function of the BCSFB. We propose
that under normal conditions, the BCSFB can clear a-Syn
from the CSF by degrading the protein within the barrier
cells and/or transporting the protein to the blood. Shouldyn by neurons, glia, and brain barrier cell types
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associated injury cannot be ignored.
Overall, findings discussed in this article have described
the uptake of a-Syn by astrocytes and by choroidal epithelial
cells, but these findings are merely the first step to under-
stand the potential clearance or degradation of a-Syn by
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line of research will contribute significantly to our under-
standing of synucleinopathies, particularly in PD, and
identification of new therapeutic targets.
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